|
SECURITIES AND EXCHANGE COMMISSION
|
||
|
Washington, D.C. 20549
|
||
|
SCHEDULE 13G
|
||
|
(Rule 13d-102)
|
||
|
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
|
||
|
TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED
|
||
|
PURSUANT TO RULE 13d-2(b)
|
||
|
(Amendment No. )1
|
||
|
Singular Genomics Systems, Inc.
|
||
|
(Name of Issuer)
|
||
|
Common Stock, $0.0001 par value
|
||
|
(Title of Class of Securities)
|
||
|
82933R100
|
||
|
(CUSIP Number)
|
||
|
December 31, 2021
|
||
|
Date of Event Which Requires Filing of this Statement
|
||
Check the appropriate box to designate the rule pursuant to which this Schedule is Filed:
[ ] Rule 13d-1(b)
[ ] Rule 13d-1(c)
[X] Rule 13d-1(d)
_______________________
1The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment
containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or
otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.
CUSIP No. 82933R100
|
1)
|
Name of Reporting Person
I.R.S. Identification
No. of Above Person
(Entities Only)
(Voluntary)
|
Domain Partners IX, L.P.
|
||
|
2)
|
Check the Appropriate Box
if a Member of a Group
|
(a) [X]
(b) [ ]
|
||
|
3)
|
SEC Use Only
|
|||
|
4)
|
Citizenship or Place
of Organization
|
Delaware
|
||
|
Number of
Shares Beneficially
Owned by Each
Reporting Person
With
|
5)
|
Sole Voting
Power |
4,395,633 shares of Common Stock *
|
|
|
6)
|
Shared Voting
Power |
-0-
|
||
|
7)
|
Sole Dispositive
Power |
4,395,633 shares of Common Stock *
|
||
|
8)
|
Shared Dispositive Power
|
-0-
|
||
|
9)
|
Aggregate Amount Beneficially Owned by Each Reporting Person
|
4,395,633 shares of Common Stock *
|
||
|
10)
|
Check if the Aggregate Amount in Row (9) Excludes Certain Shares
|
|||
|
11)
|
Percent of Class Represented by Amount in Row (9)
|
6.1% **
|
||
|
12)
|
Type of Reporting Person
|
PN
|
||
* As of December 31, 2021
** Based on 72,058,523 shares of Common Stock outstanding as of October 31, 2021, as reported in the Issuer’s Report on Form 10-Q for the period ended September 30, 2021 filed with the Securities and Exchange Commission on
November 9, 2021
2
CUSIP No. 82933R100
|
1)
|
Name of Reporting Person
I.R.S. Identification
No. of Above Person
(Entities Only)
(Voluntary)
|
Domain Associates, LLC
|
||
|
2)
|
Check the Appropriate Box
if a Member of a Group
|
(a) [X]
(b) [ ]
|
||
|
3)
|
SEC Use Only
|
|||
|
4)
|
Citizenship or Place
of Organization
|
Delaware
|
||
|
Number of
Shares Beneficially
Owned by Each
Reporting Person
With
|
5)
|
Sole Voting
Power |
15,000 shares of Common Stock *
|
|
|
6)
|
Shared Voting
Power |
-0-
|
||
|
7)
|
Sole Dispositive
Power |
15,000 shares of Common Stock *
|
||
|
8)
|
Shared Dispositive Power
|
-0-
|
||
|
9)
|
Aggregate Amount Beneficially Owned by Each Reporting Person
|
15,000 shares of Common Stock *
|
||
|
10)
|
Check if the Aggregate Amount in Row (9) Excludes Certain Shares
|
|||
|
11)
|
Percent of Class Represented by Amount in Row (9)
|
Less than 0.1% **
|
||
|
12)
|
Type of Reporting Person
|
PN
|
||
* As of December 31, 2021
** Based on 72,058,523 shares of Common Stock outstanding as of October 31, 2021, as reported in the Issuer’s Report on Form 10-Q for the period ended September 30, 2021 filed with the Securities and Exchange Commission on
November 9, 2021
3
CUSIP No. 82933R100
Schedule 13G
| Item 1(a) |
Name of Issuer:
|
Singular Genomics Systems, Inc.
| Item 1(b) |
Address of Issuer’s Principal Executive Offices:
|
10931 N. Torrey Pines Road, Suite 100, La Jolla, CA 92037
| Item 2(a) |
Name of Person Filing:
|
This statement is being filed by Domain Partners IX, L.P., a Delaware limited partnership (“Domain IX”), and Domain Associates, LLC, a Delaware limited liability company (“DA” and together with Domain IX, the “Reporting
Persons”). The Joint Filing Agreement between the Reporting Persons is attached hereto as Exhibit A.
One Palmer Square Associates IX, LLC, a Delaware limited liability company (“OPSA IX”), is the sole general partner of Domain IX and therefore may be deemed to indirectly beneficially own the securities reported herein as
directly beneficially owned by Domain IX, however OPSA IX expressly disclaims beneficial ownership of such securities.
| Item 2(b) |
Address of Principal Business Office:
|
For each Reporting Person: 103 Carnegie Center, Suite 300, Princeton, NJ 08540
| Item 2(c) |
Place of Organization:
|
Domain IX: Delaware
DA: Delaware
| Item 2(d) |
Title of Class of Securities:
|
Common Stock, $0.0001 par value
| Item 2(e) |
CUSIP Number:
|
82933R100
| Item 3 |
Statements Filed Pursuant to Rules 13d-1(b) or 13d-2(b):
|
Not applicable.
4
CUSIP No. 82933R100
| Item 4 |
Ownership:
|
(a) through (c): The information requested in these paragraphs is incorporated herein by reference to the cover pages to this Schedule 13G.
| Item 5 |
Ownership of Five Percent or Less of a Class:
|
Not applicable.
| Item 6 |
Ownership of More than Five Percent on Behalf of Another Person:
|
Not applicable.
| Item 7 |
Identification and Classification of Subsidiary:
|
Not applicable.
| Item 8 |
Identification and Classification of Members of Group:
|
Not applicable.
| Item 9 |
Notice of Dissolution of Group:
|
Not applicable.
| Item 10 |
Certification:
|
Not applicable.
5
CUSIP No. 82933R100
Signature:
After reasonable inquiry and to the best of the undersigned’s knowledge and belief, the undersigned hereby certifies that the information set forth in this statement is true, complete and correct.
Dated: January 4, 2022
|
DOMAIN PARTNERS IX, L.P.
|
|||
|
By:
|
One Palmer Square Associates IX, L.L.C., General Partner
|
||
|
By:
|
/s/ Lisa A. Kraeutler
|
||
|
Attorney-in-Fact *
|
|||
|
DOMAIN ASSOCIATES, LLC
|
|||
|
By:
|
/s/ Lisa A. Kraeutler
|
||
|
Attorney-in-Fact
|
|||
_________________________________________________
*pursuant to Power of Attorney attached hereto as Exhibit B
6
CUSIP No. 82933R100
EXHIBIT A
JOINT FILING AGREEMENT
The undersigned hereby agree that the statement on Schedule 13G to which this Agreement is annexed as Exhibit A, and any amendments thereto, is and will be filed on behalf of each of them in accordance with the provisions of
Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.
Dated: January 4, 2022
|
DOMAIN PARTNERS IX, L.P.
|
|||
|
By:
|
One Palmer Square Associates IX, L.L.C., General Partner
|
||
|
By:
|
/s/ Lisa A. Kraeutler
|
||
|
Attorney-in-Fact *
|
|||
|
DOMAIN ASSOCIATES, LLC
|
|||
|
By:
|
/s/ Lisa A. Kraeutler
|
||
|
Attorney-in-Fact
|
|||
_________________________________________________
*pursuant to Power of Attorney attached hereto as Exhibit B
7
CUSIP No. 82933R100
EXHIBIT B
POWER OF ATTORNEY
THE UNDERSIGNED hereby makes, constitutes and appoints Lisa A. Kraeutler and Nicole Vitullo (each an “Attorney”), with full power of substitution, each a true and lawful attorney-in-fact for the undersigned, in the
undersigned’s name, place and stead and on the undersigned’s behalf, to complete, execute and file with the United States Securities and Exchange Commission (the “Commission”), one or more initial statements of beneficial ownership of securities,
statements of changes in beneficial ownership of securities, annual statements of beneficial ownership of securities and/or information statements pursuant to Sections 16(a), 13(d) and 13(g) of the Securities Exchange Act of 1934 and the rules and
regulations thereunder, and any other forms, certificates, documents or instruments that the Attorney deems necessary or appropriate in order to comply with the requirements of said Sections 16(a), 13(d) and 13(g) and said rules and regulations.
This Power of Attorney shall remain in effect until a written revocation thereof is filed with the Commission.
Dated: January 22, 2016
|
DOMAIN PARTNERS IX, LP
|
|||
|
By:
|
One Palmer Square Partners IX, LLC,
its General Partner
|
||
|
By:
|
/s/ James C. Blair
|
||
|
James C. Blair, Managing Member
|
|||
8